Zymeworks
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +4.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 8.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 49.3x | Better than 10% |
| Forward P/E | 33.5x | Better than 14% |
| Price / Sales | 6.8x | Better than 16% |
| P/E vs own 5-yr range | 100th pctl | Better than 2% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -87.3% | Better than 8% |
| Net margin | -76.6% | Better than 7% |
| Return on equity | -26.7% | Better than 14% |
| Return on invested capital | -28.3% | Better than 11% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -8.8% | Better than 53% |
| 6-month return | 2.1% | Better than 59% |
| 12-month return (ex latest month) | 17.5% | Better than 56% |
| Distance below 52-week high | 18.2% | Better than 64% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 5.9x | Better than 88% |
| Debt to assets | 5.3% | Better than 79% |
| Interest coverage | -206.1x | Better than 4% |
| Free cash flow / net income | 105.3% | Better than 42% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 60.0% | Better than 72% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 26.86
- Open
- 26.30
- Day range
- 26.09 - 27.57
- Avg price
- 26.57
- Volume
- 738.81K
- Turnover
- 19.63M
- Turnover ratei
- 1.14%
- Volume ratioi
- 0.84
- Amplitudei
- 5.51%
- 52-week rangei
- 21.52 - 31.97
Valuation
- P/Ei
- -24.20
- P/E (TTM)i
- 49.32
- P/Bi
- 7.00
- EPSi
- -1.08
- Book value / shi
- 3.73
- Net profit
- -74.71M
- Net assets
- 258.29M
Share structure
- Market cap
- 1.81B
- Float capi
- 1.69B
- Shares out
- 69.17M
- Float sharesi
- 64.69M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2017-04-28
18.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-13.03M net over the window
Short interest
- Shares short
- 5.91M
- % of floati
- 8.39%
- Days to coveri
- 4.25
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Zymeworks (ZYME)?
Zymeworks last traded at 26.14. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Zymeworks's market cap?
About 1.81B.
What is the P/E ratio of Zymeworks?
The trailing twelve-month P/E is 49.32. The Valuation tab shows it against the stock's own five-year range.
Does Zymeworks pay a dividend?
Zymeworks does not currently pay a regular dividend.
Is Zymeworks a buy according to analysts?
The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 41.83, which implies 60.0% upside from the current price. This is not investment advice.
What is Zymeworks's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Zymeworks a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Zymeworks discussion 0 comments